Press Release / Media Release
Cadila's Dabhasa API facility successfully completes USFDA inspection19-01-2018
19-01-2018
Statement Of Investor Complaint For The Quarter Ended On December 31, 2017
Statement of Investor Complaint for the quarter ended on December 31, 201712-01-2018
Shareholding for the Period Ended December 31, 2017
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here11-01-2018
Board Meeting On 08-02-2018
We hereby inform that the meeting of the Board of Directors of the Company will be held on Thursday, February 8, 2018 to consider apart from other agenda items to approve the unaudited financial results for the quarter / nine months ended on December 31, 2017. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain...10-01-2018
Press Release / Media Release
Zydus receives final approval from the USFDA for Valacyclovir Tablets USP30-12-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Clomipramine Hydrochloride Capsules USP.29-12-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Nifedipine Extended-Release Tablets USP21-12-2017
Cadila Healthcare says Zydus got USFDA nod to market two drugs
Received final approval to treat Parkinson's disease and acute uncomplicated urinary tract infections14-12-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Pramipexole Dihydrochloride Extended-Release Tablets and Nitrofurantoin Capsules USP (macrocrystals)14-12-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Clozapine Tablets USP08-12-2017